Creabilis appoints new chief executive
Eliot Forster brings significant drug development experience to firm
Forster brings almost 20 years’ industry experience in biotechnology and pharmaceutical companies to the Luxembourg-based firm.
He was most recently chief executive of Solace Pharmaceuticals, a US-based biotech. Prior to this, was Pfizer’s head of EU development and of development operations in the EU and Asia. During his career at Pfizer Forster was integral to bringing a number of drugs to market, including Celebrex (celecoxib), Bextra (valcecoxib) and Relpax (eletriptan).
Creabilis’ lead product is CT327, a novel topically applied TrkA kinase inhibitor developed using the Company’s LSE (Low Systemic Exposure) technology. It is currently in Phase II clinical trials in psoriasis and atopic dermatitis.
The Creabilis portfolio also includes CT637, a new approach to the treatment of significant inflammatory conditions such as rheumatoid arthritis as well as severe psoriasis.
You may also like
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Regulatory
FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection
The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Research & Development
Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer
The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Manufacturing
Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market
Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA